Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Depreciation & Amortization (CF) (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Depreciation & Amortization (CF) data on record, last reported at $11000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 69.44% year-over-year to $11000.0; the TTM value through Sep 2025 reached $79000.0, down 41.04%, while the annual FY2024 figure was $137000.0, 21.24% up from the prior year.
  • Depreciation & Amortization (CF) reached $11000.0 in Q3 2025 per ZBIO's latest filing, down from $12000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $36000.0 in Q3 2024 and bottomed at $11000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 3 years is $26625.0, with a median of $31500.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): rose 10.0% in 2024, then tumbled 69.44% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $30000.0 in 2023, then grew by 10.0% to $33000.0 in 2024, then tumbled by 66.67% to $11000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $11000.0 in Q3 2025, $12000.0 in Q2 2025, and $23000.0 in Q1 2025.